ArticleFrontiers in veterinary science2025
Two proteins, one goal: ELISAs based on p32 and L1R for LSDV antibodies detection.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a monoclonal antibody-based competitive ELISA for serological detection of lumpy skin disease virus.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lumpy skin disease virus (LSDV), a member of the Methods: In this study, we produced and evaluated two recombinant LSDV antigens: ORF074 (p32), a well-known immunodominant protein, and ORF060 (homologous to the Vaccinia virus L1R), a myristoylated membrane protein identified as a promising immunogenic target. Both proteins were expressed in Results and discussion: Both assays demonstrated high immunoreactivity and strong concordance with the VNT. These results support the suitability of both antigens for use in serological assays and suggest that a combined, multi-target ELISA approach could enhance diagnostic sensitivity. Once validated for routine use, these novel tools may significantly improve large-scale, cost-effective serological surveillance of LSDV in endemic and at-risk regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.